Efficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell lymphoma: a single-center retrospective analysis

• Published in: Clinical and experimental medicine Vol. 23; no. 8; pp. 4609 - 4621
• Main Authors: Wei, Ruowen, Wu, Yingying, Jiang, Shan, Zhang, Ao, Zhang, Lu, Liu, Ling, Wang, Yadan, Zhang, Min, Mei, Heng, Liu, Fang, Xia, Linghui, Cui, Guohui, Fang, Jun
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.12.2023; Springer Nature B.V
• Subjects: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols - adverse effects; B-cell lymphoma; Bronchopulmonary infection; Bruton's tyrosine kinase; Chemotherapy; Clinical Practice; Hematology; Humans; Immunotherapy; Internal Medicine; Lymphocytes B; Lymphoma; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - pathology; Medicine; Medicine & Public Health; Middle Aged; Neutropenia; Oncology; Protein-tyrosine kinase; Response rates; Retrospective Studies; Rituximab; Thrombocytopenia; Orelabrutinib; Diffuse large B-cell lymphoma
• ISSN: 1591-9528; 1591-8890; 1591-9528
• DOI: 10.1007/s10238-023-01231-w

Currently, combining chemotherapy with Bruton tyrosine kinase inhibitors (BTKi) has demonstrated significant effectiveness in treating patients with diffuse large B-cell lymphoma. Orelabrutinib is a second-generation BTK inhibitor, and presently, there have been few reports of Orelabrutinib being used to treat DLBCL. We conducted a retrospective investigation to explore the safety and efficacy of Orelabrutinib in combination with chemotherapy or immunotherapy. The study comprised 19 patients with a median age of 61 years. The overall response rate (ORR) was 89.5% with a complete response (CR) rate of 73.7% and a partial response rate (PR) of 15.8%. The estimated 2-year overall survival (OS) and progression-free survival (PFS) rates were 78.6% (95%CI, 59.8%–100%) and 72.2% (95% CI, 52.4%–99.6%), respectively, with a median follow-up time of 11 months (range 2–24). The most prevalent grade 3 or 4 adverse events (AEs), neutropenia (52.6%), anemia (36.8%), thrombocytopenia (26.3%), febrile neutropenia (26.3%), and lung infection (10.5%), were the most common. Our results reveal that Orelabrutinib is an effective therapy for DLBCL patients. Furthermore, our first investigation of the Orelabrutinib application lays a foundation for larger retrospective studies.